Below are the most recent publications written about "Uveal Neoplasms" by people in Profiles.
-
Varney SD, Erkes DA, Mersky GL, Mustafa MU, Chua V, Chervoneva I, Purwin TJ, Alnemri E, Aplin AE. Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma. Mol Cancer Res. 2025 04 01; 23(4):350-362.
-
Calabresi K, Emrich J, Belko S, Pugliese R, Komarnicky-Kocher L, Mourtada F. 3D-printed template design to improve 125I seed plaque assembly accuracy for uveal brachytherapy. Brachytherapy. 2025 May-Jun; 24(3):420-430.
-
August AH, Cernichiaro-Espinosa LA, Moctezuma-Davila M, Wibbelsman TD, Wilson MW, Ch?vez-Barrios P, Shields CL, Lally SE, Eberhart CG, Orr BA, Simpson E, Eagle RC, Milman T. Ciliary Body Medulloepithelioma: Clinical and Pathologic Challenges with a Focus on Molecular Genetics. Semin Ophthalmol. 2025 Aug; 40(6):518-528.
-
Cappelli L, Khan MM, Shields CL, Lally SE, Sharif M, Liu H, Chen Y, Park J, Zhan T, Shi W. Favorable Outcomes of Patients With High-Risk Uveal Melanoma Treated With a Novel Linear Accelerator-Based Frameless Fractionated Stereotactic Radiosurgery. Am J Ophthalmol. 2025 Mar; 271:417-423.
-
Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. Eur J Cancer. 2025 Jan; 214:115161.
-
Mourtada F, Belko S, Monane R, Pugliese R, Komarnicky-Kocher L, Lally SE, Wang W, Shields CL, Emrich J. A novel 3D printing method for a notched eye plaque "dummy" for uveal melanoma brachytherapy. Brachytherapy. 2025 Jan-Feb; 24(1):86-91.
-
Dalvin LA, Andrews-Pfannkoch CM, Miley DR, Hogenson TL, Erickson SA, Malpotra S, Anderson KJ, Omer ME, Almada LL, Zhang C, Li H, Salomao DR, Shields CL, Lally SE, Malsch RM, Armitage JA, Holmes HL, Romero MF, Fautsch MP, Markovic SN, Fernandez-Zapico ME. Novel Uveal Melanoma Patient-Derived Organoid Models Recapitulate Human Disease to Support Translational Research. Invest Ophthalmol Vis Sci. 2024 11 04; 65(13):60.
-
Seedor RS, Aplin AE, Bertolotto C, Carvajal RD, Deacon N, Doble K, Hamid O, Haq R, Kadosh M, Khan S, Kraska J, Lutzky J, McKean M, Montazeri K, Moser J, Onken M, Orloff M, Sacco JJ, Smalley K, Selig SM. Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023. Pigment Cell Melanoma Res. 2025 01; 38(1):e13205.
-
Harbour JW, Correa ZM, Schefler AC, Mruthyunjaya P, Materin MA, Aaberg TA, Skalet AH, Reichstein DA, Weis E, Kim IK, Fuller TS, Demirci H, Piggott KD, Williams BK, Shildkrot E, Capone A, Oliver SC, Walter SD, Mason J, Char DH, Altaweel M, Wells JR, Duker JS, Hovland PG, Gombos DS, Tsai T, Javid C, Marr BP, Gao A, Decatur CL, Dollar JJ, Kurtenbach S, Zhang S. 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). J Clin Oncol. 2024 10; 42(28):3319-3329.
-
Chua V, Lopez-Anton M, Baqai U, Purwin TJ, Haj JI, Waltrich FJ, Trachtenberg I, Luo K, Tudi R, Jeon A, Han A, Chervoneva I, Davies MA, Aguirre-Ghiso JA, Sato T, Aplin AE. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. Sci Signal. 2024 06 11; 17(840):eadn8376.